Eikon Therapeutics, Inc. Common Stock (EIKN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) has a cash flow conversion efficiency ratio of 0.047x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.72 Million) by net assets ($-879.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eikon Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Eikon Therapeutics, Inc. Common Stock (EIKN) total liabilities for a breakdown of total debt and financial obligations.
Eikon Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eikon Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DRB - Hicom Bhd
KLSE:1619
|
0.079x |
|
Shenzhen Kexin Communication Technologies Co Ltd
SHE:300565
|
-0.061x |
|
Olympic Steel Inc
NASDAQ:ZEUS
|
-0.009x |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
-0.002x |
|
Hangzhou Guotai Environmental Protection Technology Co. Ltd. A
SHE:301203
|
N/A |
|
Unity Bancorp Inc
NASDAQ:UNTY
|
0.042x |
|
Sebang Global Battery Co Ltd
KO:004490
|
0.048x |
|
Black Cat Syndicate Ltd
AU:BC8
|
-0.041x |
Annual Cash Flow Conversion Efficiency for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Eikon Therapeutics, Inc. Common Stock from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see EIKN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-879.03 Million | $-188.52 Million | 0.214x | -9.01% |
| 2024-12-31 | $-571.93 Million | $-134.80 Million | 0.236x | -57.84% |
| 2023-12-31 | $-341.37 Million | $-190.85 Million | 0.559x | -- |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more